AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9839764
Drug: Theophylline in
RxNorm normalized name: theophylline Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline in combination with donepezil (5 mg, once daily for 10 days)
Trial: 2572652
Drug: Ranitidine, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 300 mg
Trial: 998148
Drug: Atropine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.1 mg/10 kg intravenously 2 min before induction)
Trial: 31331572
Drug: Placebo, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, twice daily for 4 weeks
Trial: 26008138
Drug: Intravenous doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous doxycycline 200, 100 and 100mg
Trial: 26008138
Drug: Intravenous doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous doxycycline 100, 50 and 50mg
Trial: 24094495
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion of growth hormone (3mg/24h) for 60 hours
Trial: 21724796
Drug: RENEW program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RENEW program (meal replacements twice daily, intensive instruction in nutrition and meal preparation, exercise, and goal setting for three months)
Trial: 17072091
Drug: Atropine (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.01 mg kg(‐1))
Trial: 8953321
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT) for bulimia nervosa
Trial: 1411629
Drug: Carboplatin 60
RxNorm normalized name: CARBOPLATIN 600MG/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin 60 mg/m2 with 67.2 Gy radiation
Trial: 1411629
Drug: Simultaneous chemoradiotherapy
RxNorm normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous chemoradiotherapy (various carboplatin doses with radiation)
Trial: 1411629
Drug: Sequential chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemoradiotherapy (carboplatin/5-fluorouracil followed by conventional radiotherapy)
Trial: 31087542
Drug: TCZ‐SC 162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCZ‐SC 162 mg q2w
Trial: 27872513
Drug: Lactoferrin (LF)
DrugBank: Lactoferrin (DB16555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactoferrin (LF) administration 4 hours before amniocentesis
Trial: 27872513
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no LF treatment)
Trial: 22809012
Drug: Pazufloxacin mesilate
RxNorm normalized name: pazufloxacin
DrugBank: Pazufloxacin (DB11774)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazufloxacin mesilate 300 mg
Trial: 22809012
Drug: Pazufloxacin mesilate
RxNorm normalized name: pazufloxacin
DrugBank: Pazufloxacin (DB11774)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazufloxacin mesilate 500 mg
Trial: 22809012
Drug: Pazufloxacin mesilate
RxNorm normalized name: pazufloxacin
DrugBank: Pazufloxacin (DB11774)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazufloxacin mesilate 600 mg
Trial: 22809012
Drug: Pazufloxacin mesilate
RxNorm normalized name: pazufloxacin
DrugBank: Pazufloxacin (DB11774)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazufloxacin mesilate 1,000 mg
Trial: 17583378
Drug: Risk factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk factors for lacking medications
Trial: 15821120
Drug: Gemcitabine 1200
RxNorm normalized name: gemcitabine 1200 MG in 120 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1200 mg/m² on days 1, 8, and 15 of a 28-day cycle
Trial: 15821120
Drug: Epirubicin 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 35 mg/m² on days 1, 8, and 15 of a 28-day cycle
Trial: 31436705
Drug: Small-quantity lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-quantity lipid-based nutrient supplement provided to pregnant and lactating mothers and their children
Trial: 28798089
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (n=156)
Trial: 23924586
Drug: DRV/r 800/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV/r 800/100 mg once daily (OD) monotherapy
Trial: 23924586
Drug: DRV/r 800/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV/r 800/100 mg OD plus 2 nucleoside reverse transcriptase inhibitors (NRTIs)
Trial: 20625394
Drug: Solar simulated
RxNorm normalized name: Bos taurus solar plexus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solar simulated radiation (SSR) at doses of 2 and 4 J/cm²
Trial: 11189100
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (Cisplatin 100 mg/m2 on day 1 and fluorouracil 1000 mg/m2/day for 5 days, every 21 days) followed by loco-regional treatment.
Trial: 11189100
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy followed by loco-regional treatment.
Trial: 11189100
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (Cisplatin and fluorouracil) followed by loco-regional treatment.
Trial: 7504379
Drug: Killed Mycobacterium
RxNorm normalized name: Heat Killed Mycobacterium W Immunomodulator
DrugBank: Mycobacterium w. Vaccine (DB15798)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killed Mycobacterium leprae vaccine
Trial: 2990332
Drug: Paper tissues
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paper tissues treated with a combination of citric acid, malic acid, and sodium lauryl sulfate
Trial: 30400977
Drug: Antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drugs (urapidil, nicardipine, labetalol)
Trial: 18476430
Drug: Shuxuetong Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuxuetong Injection (SXTI) high dose (8 mL/d)
Trial: 18476430
Drug: Shuxuetong Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuxuetong Injection (SXTI) low dose (6 mL/d)
Trial: 15546907
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg zoledronic acid iv, administered as three monthly doses
Trial: 10530684
Drug: Gabapentin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (up to 3600 mg per day)
Trial: 3047380
Drug: Sulindac 400
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulindac 400 mg daily
Trial: 3047380
Drug: Sulindac 600
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulindac 600 mg daily
Trial: 26032168
Drug: Quinine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (80 mg)
Trial: 26032168
Drug: Oxycodone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (30 mg)
Trial: 26032168
Drug: Quinine and
RxNorm normalized name: quinine and urea HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine and Oxycodone (80 mg and 30 mg respectively)
Trial: 23530757
Drug: Intramuscular magnesium
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular magnesium sulphate regimen
Trial: 23530757
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate regimen
Trial: 22059194
Drug: Tapentadol IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol IR (50 mg or 100 mg every 4 to 6 hours as needed)
Trial: 22059194
Drug: Oxycodone IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone IR (10 mg or 15 mg every 4 to 6 hours as needed)
Trial: 11968154
Drug: rhuMAb CD18
RxNorm normalized name: rhuMAb 2H7
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: rhuMAb CD18 (0.06, 0.12, 0.25, 0.5, 1.0, 2.0 mg/kg)
Trial: 11968154
Drug: rhuMAb CD18
RxNorm normalized name: rhuMAb 2H7
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: rhuMAb CD18 (doses above 0.06 mg/kg)
Trial: 9893888
Drug: Evidence Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence Based Emergency Medicine (EBEM) practices
Trial: 7923513
Drug: Subcutaneous infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous infiltration (group SC)
Trial: 3072446
Drug: Anti-anginal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-anginal therapy
Trial: 24510005
Drug: Brilliant Blue
RxNorm normalized name: Brilliant blue G
DrugBank: Brilliant blue G (DB15594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brilliant Blue G (BBG) applied at 0.2 mL for 2 minutes under air conditions during ERM surgery
Trial: 16202043
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity laser therapy (LILT) with infrared laser (780 nm, 30 mW, 10 s, 6.3 J/cm(2))
Trial: 16202043
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity laser therapy (LILT)
Trial: 12076869
Drug: 5 MU
RxNorm normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 MU of interferon alpha 2b combined with ribavirin (1000-1200 mg daily)
Trial: 12076869
Drug: 3 MU
RxNorm normalized name: Orasep Reformulated Dec 2013 Mucosal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 MU of interferon alpha 2b combined with ribavirin (1000-1200 mg daily)
Trial: 2141612
Drug: Captopril (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (average daily dose 269 mg, range 150 to 300)
Trial: 2141612
Drug: Minoxidil (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minoxidil (average daily dose 20 mg, range 7.5 to 30)
Trial: 11119398
Drug: MDMA (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (0.5 mg/kg)
Trial: 25735993
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug administration (Study 1)
Trial: 21954280
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (OC) treatment
Trial: 21954280
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral contraceptive (non-OC) treatment
Trial: 17143257
Drug: Bevacizumab in
RxNorm normalized name: bevacizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab in combination with chemotherapy (paclitaxel plus carboplatin)
Trial: 17143257
Drug: Bevacizumab in
RxNorm normalized name: bevacizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab in combination with erlotinib
Trial: 17143257
Drug: Other antiangiogenic
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antiangiogenic approaches (small‐molecule tyrosine kinase inhibitors)
Trial: 1284161
Drug: GSR 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSR 100 mg
Trial: 6741684
Drug: Treatment joiners
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment joiners
Trial: 24493633
Drug: Daily crossword
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily crossword intervention for 4 weeks
Trial: 24493633
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily gratitude diary for 4 weeks)
Trial: 22471295
Drug: SLCaps (soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLCaps (soft gelatin capsules)
Trial: 22471295
Drug: HPCaps (hard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPCaps (hard gelatin capsules)
Trial: 22471295
Drug: Intravenous vinflunine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vinflunine
Trial: 22471295
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral formulations (SLCaps and HPCaps)
Trial: 16291601
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) with clopidogrel and standard fibrinolytic and aspirin
Trial: 7725867
Drug: Meperidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 0.5 mg/kg with epinephrine (14 patients)
Trial: 7725867
Drug: Meperidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 0.5 mg/kg without epinephrine (16 patients)
Trial: 2639069
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline solution mouth rinse
Trial: 28386788
Drug: Compression-only therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression-only therapy (CT)
Trial: 17313717
Drug: Iron absorption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron absorption efficiency
Trial: 15449742
Drug: Propofol (2-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2-5 mg kg(‐1) h(‐1))
Trial: 9754479
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine 20 mg orally (dose 1) and 10 mg (dose 2)
Trial: 9754479
Drug: Hydrocodone 10
RxNorm normalized name: HYDROCODONE 10/PPA 25MG/5ML SYRUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone 10 mg plus acetaminophen 1,000 mg orally (both doses)
Trial: 8313331
Drug: DAB486IL-2 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAB486IL-2 at 0.2 mg/kg daily for 5 days
Trial: 8313331
Drug: DAB486IL-2 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAB486IL-2 at 0.075 mg/kg and 0.115 mg/kg
Trial: 3416497
Drug: Methylphenidate (MP)
RxNorm normalized name: 6 MP
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MP) at doses of 0.1 and 0.33 mg/kg three times daily
Trial: 3416497
Drug: Methylphenidate (MP)
RxNorm normalized name: 6 MP
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MP) at high dose
Trial: 1070466
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus immunotherapy (BCG and irradiated allogeneic myeloblastic leukaemia cells)
Trial: 25042729
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of grid laser and IVR
Trial: 23414646
Drug: Cognitive Intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Intervention Program (CIP) for 6 months, 2 hours per session, twice per week.
Trial: 21195572
Drug: 550 mg
RxNorm normalized name: xylitol 550 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 550 mg iodine/(kg of LBW)
Trial: 21195572
Drug: 650 mg
RxNorm normalized name: bran 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg iodine/(kg of LBW)
Trial: 21195572
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg iodine/(kg of LBW)
Trial: 21195572
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg iodine/(kg of TBW)
Trial: 11843764
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous immunoglobulin (IVIG) treatment
Trial: 16042771
Drug: Steroid-naïve asthmatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-naïve asthmatic children
Trial: 16042771
Drug: Inhaled steroid-treated
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled steroid-treated asthmatic children
Trial: 16042771
Drug: Steroid-treated asthmatic
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-treated asthmatic children
Trial: 8694167
Drug: Propofol +
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol + Ephedrine 15 mg
Trial: 8694167
Drug: Propofol +
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol + Ephedrine 20 mg
Trial: 8694167
Drug: Propofol +
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol + Ephedrine 10 mg
Trial: 6507998
Drug: Low-dose methylprednisolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methylprednisolone (32 mg)
Trial: 6507998
Drug: High-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methylprednisolone (128 mg)
Trial: 20375690
Drug: Revascularization and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revascularization and medical therapy
Trial: 20375690
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy alone and deferred or no revascularization
Trial: 20375690
Drug: Glycemic control
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycemic control with insulin‐providing or insulin‐sensitizing drugs
Trial: 18036421
Drug: Olopatadine nasal
RxNorm normalized name: olopatadine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olopatadine nasal spray 0.2%
Trial: 18036421
Drug: Olopatadine nasal
RxNorm normalized name: olopatadine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olopatadine nasal spray 0.4%
Trial: 18036421
Drug: Olopatadine nasal
RxNorm normalized name: olopatadine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olopatadine nasal spray 0.6%
Trial: 2210238
Drug: Injection therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection therapy with absolute ethanol
Trial: 25867812
Drug: MTZ 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTZ 30 mg/d for 42 days
Trial: 19585653
Drug: Viramidine (VRD)
RxNorm normalized name: lidamidine
DrugBank: Taribavirin (DB06408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viramidine (VRD) 600 mg BID
Trial: 19585653
Drug: Ribavirin (RBV)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin (RBV) weight-based (1000 or 1200 mg/day)
Trial: 15539716
Drug: Zafirlukast 20
RxNorm normalized name: zafirlukast 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zafirlukast 20 mg (Z20)
Trial: 15539716
Drug: Zafirlukast 160
RxNorm normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zafirlukast 160 mg (Z160)
Trial: 11815725
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose testosterone (LDT) 62.5 mg/m2
Trial: 11815725
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose testosterone (CDT) 125 mg/m2
Trial: 11815725
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose testosterone (MDT) 62.5 mg/m2
Trial: 11815725
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose testosterone (LDT)
Trial: 11815725
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose testosterone (CDT)
Trial: 9431481
Drug: Acetylcholine or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcholine or ergonovine maleate administration
Trial: 6814472
Drug: Ro 15-1788
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15-1788 (200 mg)
Trial: 3668844
Drug: Diazepam (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (40 mg)
Trial: 25163405
Drug: Epinastine 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinastine 0.05% ophthalmic solution
Trial: 22739038
Drug: Placebo ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ophthalmic solution
Trial: 12852709
Drug: Olopatadine 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olopatadine 0.1% ophthalmic solution
Trial: 22530938
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT) program, 8 weekly sessions of 2½ hours each.
Trial: 22530938
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT) program
Trial: 11944589
Drug: Etizolam administered
RxNorm normalized name: Estazolam
DrugBank: Estazolam (DB01215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etizolam administered after hematoma removal
Trial: 3768247
Drug: Cimetidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1 g day‐1 for 7 days)